Global Information
회사소개 | 문의 | 비교리스트

임상시험 부문 스코어카드(2021년 4분기 업데이트)

Clinical Trials Sector Scorecard - Q4 2021 Update - Thematic Research

리서치사 GlobalData
발행일 2021년 12월 상품코드 1054039
페이지 정보 영문 17 Pages 배송안내
US $ 1,950 ₩ 2,484,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,900 ₩ 4,969,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,850 ₩ 7,454,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

임상시험 부문 스코어카드(2021년 4분기 업데이트) Clinical Trials Sector Scorecard - Q4 2021 Update - Thematic Research
발행일 : 2021년 12월 페이지 정보 : 영문 17 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

2021년 4분기에 ESG 활동은 사회(Social) 및 거버넌스(Governance)와 비교하여 환경 구상이 대부분을 차지한 것으로 예상됩니다. 2021년 4분기에는 사회 및 거버넌스에 관한 주요 지속가능성 활동은 없었으나, 많은 기업이 새로운 환경 구상을 발표하고 있습니다. 또한 2021년 4분기에는 '인공지능', '가상 케어', '사이버 보안', 'RWE(Real-World Evidence)' 활동도 개시하고 있습니다.

세계의 임상시험 부문 스코어카드에 대해 조사분석했으며, 제약 테마 맵, 임상시험 스코어카드, 테마 조사 방법 등의 정보를 정리하여 전해드립니다.



  • 개요
  • 서론
  • 제약 테마 맵
  • 임상시험 스코어카드 : 2021년 4분기의 주요 업데이트
  • 기업별
  • 테마별
  • 평가별
  • 테마 조사 방법
  • 제약기업 스코어의 생성 방법
  • 관련 리포트
  • 저자 소개
  • GlobalData 소개
KSA 22.02.09

Most Q4 2021 Activity in ESG Seen in Environmental Initiatives Compared to Social or Governance: In Q4 2021, no major social or governance sustainability activity was detected, however many companies announced new environmental initiatives. For example, AstraZeneca was the only pharma company to have its net zero targets verified by Science Based Targets in line with its new Net Zero Standard. At the 26th United Nations (UN) Climate Change Conference (COP26), the company was also named as one of the first holders of the Terra Carta Seal in recognition of its sustainability efforts, and it was also announced that AstraZeneca was one of 10 pharma companies in the Energize program, a collaboration that supports decarbonization of pharma value chains. Sanofi announced that it had joined the UN's Race to Zero initiative, which aims to get cities, regions, investors, and top companies to commit to net zero carbon emissions by 2050. Teva issued a sustainability bond linked to both social and environmental targets. GSK announced a significant investment in renewable energy and carbon reduction at manufacturing sites, as well as a new initiative to reduce GHG emissions from its inhalers. Astellas announced that it had begun using biomass-based plastics in blister packages for its products.

Artificial Intelligence, Virtual Care, Cybersecurity, and Real-World Evidence Also Saw Activity in Q4 2021: Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since September 2021. This includes collaborations between Gilead and Amazon Web Services (AWS), Roche and Recursion Pharma, Sanofi and Deloitte, and AstraZeneca with Tempus and with Oncoshot. In virtual care, companies including AbbVie, Sanofi, Eli Lilly, Boehringer Ingelheim, and Biogen posted several jobs relating to virtual trials and initiated trials with virtual components in Q4 2021. Similarly, Sanofi, Johnson & Johnson (J&J), Merck & Co, and Pfizer posted high numbers of jobs relating to cybersecurity in Q4 2021. In real-world evidence (RWE), Merck & Co announced a new collaboration with Syapse to leverage real-world data (RWD) in oncology.


  • GlobalData's Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years.
  • These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
  • The scorecard includes 54 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
  • The methodology section contains information on what data sources were used to generate the thematic scores for each company.
  • The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

  • Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

Table of Contents

  • Executive Summary
  • Introduction
  • Pharma Theme Map
  • Clinical Trials Scorecard: Key Q4 2021 Updates
  • Company Screen
  • Thematic Screen
  • Valuation Screen
  • Our Thematic Research Methodology
  • How Our Pharma Scores Are Generated
  • Related Reports
  • About the Authors
  • About GlobalData
Back to Top
전화 문의